Passive Immunotherapy: Cat allergen-specific IgG4 as a biological
Fachkreise Treating cat allergic patients is still a challenge for allergists, especially as traditional immunotherapy is not always an option. Passive immunotherapy could solve this problem, using cat allergen-specific IgG4 as a biological. In his presentation at EAACI 2018 Mohamed Shamji, PhD. FAAAAI at the Allergy & Clinical Immunology Inflammation, Repair and Development, National Heart & Lung Institute of Imperial College London, UK described the outcome of his fascinating trial on a monoclonal antibody. Mohamed Shamji is Senior lecturer (Associate Professor) in Immunology and Allergy, Head of the Immunomodulation and Tolerance Group, Director of the Immune Tolerance Network (ITN) Distributed Centre of Excellence for Allergy & Asthma, Chair of the Scientific Program Committee (EAACI) 2018-2020, Secretary of the EAACI Immunotherapy Interest Group (ITIG), International Fellow of the American Academy of Allergy, Asthma and Immunology (iFAAAAI), Board member of the Immunotherapy Committee of the World Allergy Organization (WAO) and Council member of the British Society of Allergy and Clinical Immunology (BSACI).